“Adverse reactions due to monoclonal antibodies in the treatment of allergic diseases. Group Positioning: Comité de Alergia a Medicamentos del Colegio Mexicano de Inmunología Clínica y Alergia (CMICA 2024-2025)”. (2025) Revista Alergia México, 72(1), pp. 52–71. doi:10.29262/fsaxnm03.